Drugs / Dual-targeting HER2 and PD-L1 CAR-T cells
Dual-targeting HER2 and PD-L1 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04684459 | Mar 2021 → Dec 2025 overdue | peritoneal carcinoma, pleural neoplasm | Sichuan University | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dual-targeting HER2 and PD-L1 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04684459 ↗ |
| Action | Deplete | “causing rapid and durable eradication of pleural and peritoneal metastatic tumors in xenograft models” PMID 36402752 ↗ Nov 2022 |
| Modality | Cell therapy | “CAR-T cells” NCT04684459 ↗ |
| Route | Intravenous | “via intravenous or thoracic/peritoneal cavity infusion” NCT04684459 ↗ |
| Route | Other | “via intravenous or thoracic/peritoneal cavity infusion” NCT04684459 ↗ |